Dyne Therapeutics (NASDAQ:DYN) Earns “Buy” Rating from Guggenheim

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reiterated by research analysts at Guggenheim in a report issued on Friday,Benzinga reports.

Several other equities analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Finally, Chardan Capital restated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Stock Up 0.2 %

DYN opened at $13.72 on Friday. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -3.85 and a beta of 1.16. Dyne Therapeutics has a 52 week low of $13.44 and a 52 week high of $47.45. The business’s 50 day moving average is $24.03 and its two-hundred day moving average is $32.59.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities analysts expect that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Activity

In other news, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares in the company, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,071 shares of company stock worth $606,476. Company insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd purchased a new stake in Dyne Therapeutics in the third quarter valued at approximately $36,000. US Bancorp DE increased its position in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the last quarter. Values First Advisors Inc. purchased a new position in Dyne Therapeutics during the third quarter worth approximately $62,000. Finally, KBC Group NV boosted its holdings in shares of Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.